Merck & Co., Inc. (MRK)
After hours:
| Previous Close | 73.89 |
| Open | 74.09 |
| Bid | 73.22 x 1800 |
| Ask | 73.34 x 1200 |
| Day's Range | 72.66 - 74.25 |
| 52 Week Range | 68.44 - 91.40 |
| Volume | |
| Avg. Volume | 16,667,671 |
| Market Cap | 185.252B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 25.88 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.76 (3.74%) |
| Ex-Dividend Date | Dec. 14, 2021 |
| 1y Target Est | N/A |
- Motley Fool
Here's Why Merck Lost Nearly $40 Billion in Value During November
Shares of pharma giant Merck (NYSE: MRK) fell by 14.9% during the month of November, according to data from S&P Global Market Intelligence. Although the drugmaker did take a hit from a clinical setback for its once-weekly oral treatment, MK-8507, for HIV-1 infection last month, the main reason Merck's stock slumped in November is the evolving situation surrounding its oral coronavirus pill molnupiravir. In brief, this COVID-19 pill, which is being jointly developed with privately held Ridgeback Biotherapeutics, exhibited a significant drop in efficacy following the final analysis of the full data set, compared to a prior interim data readout.
- Simply Wall St.
Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To US$0.69
Merck & Co., Inc. ( NYSE:MRK ) has announced that it will be increasing its dividend on the 7th of January to US$0.69...
- Yahoo Finance
Guess who pays for all those millions of COVID-19 vaccines
Omicron happened this week. So as the medical world shifts to a yet-to-be-determined degree, a question comes to mind: Who will pay for all this? In fact, who’s paid for all the COVID fighting to date?
